Shunji Hirose

627 total citations
35 papers, 233 citations indexed

About

Shunji Hirose is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Shunji Hirose has authored 35 papers receiving a total of 233 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hepatology, 15 papers in Epidemiology and 14 papers in Surgery. Recurrent topics in Shunji Hirose's work include Liver Disease Diagnosis and Treatment (12 papers), Hepatocellular Carcinoma Treatment and Prognosis (8 papers) and Hepatitis C virus research (8 papers). Shunji Hirose is often cited by papers focused on Liver Disease Diagnosis and Treatment (12 papers), Hepatocellular Carcinoma Treatment and Prognosis (8 papers) and Hepatitis C virus research (8 papers). Shunji Hirose collaborates with scholars based in Japan and Greece. Shunji Hirose's co-authors include Tatehiro Kagawa, Yoshitaka Arase, Kota Tsuruya, Koichi Shiraishi, Tetsuya Mine, Ryuzo Deguchi, Koshi Matsumoto, Michiko Suzuki, Masayuki Tatemichi and Hirohiko Sato and has published in prestigious journals such as PLoS ONE, Hepatology and Scientific Reports.

In The Last Decade

Shunji Hirose

29 papers receiving 230 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shunji Hirose Japan 11 141 128 61 60 36 35 233
Cheng‐Hung Chien Taiwan 10 87 0.6× 144 1.1× 30 0.5× 79 1.3× 61 1.7× 27 268
Zheng‐Rong Shi China 9 140 1.0× 169 1.3× 30 0.5× 79 1.3× 49 1.4× 23 291
Andrea Mega Italy 8 74 0.5× 78 0.6× 39 0.6× 53 0.9× 9 0.3× 20 211
Kuan‐Chieh Fang Taiwan 7 190 1.3× 233 1.8× 33 0.5× 39 0.7× 53 1.5× 10 296
Anastasia Katsoula Greece 7 70 0.5× 129 1.0× 65 1.1× 61 1.0× 40 1.1× 13 266
Jung Wha Chung South Korea 11 222 1.6× 236 1.8× 32 0.5× 67 1.1× 16 0.4× 24 365
Kosuke Tanaka Japan 7 43 0.3× 108 0.8× 32 0.5× 47 0.8× 36 1.0× 26 227
Ganesh Bhat India 10 86 0.6× 149 1.2× 41 0.7× 109 1.8× 31 0.9× 37 268
Takahiro Ozutsumi Japan 8 63 0.4× 122 1.0× 43 0.7× 48 0.8× 21 0.6× 18 202
Roberto Firpi-Morell United States 8 182 1.3× 290 2.3× 25 0.4× 63 1.1× 26 0.7× 14 344

Countries citing papers authored by Shunji Hirose

Since Specialization
Citations

This map shows the geographic impact of Shunji Hirose's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shunji Hirose with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shunji Hirose more than expected).

Fields of papers citing papers by Shunji Hirose

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shunji Hirose. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shunji Hirose. The network helps show where Shunji Hirose may publish in the future.

Co-authorship network of co-authors of Shunji Hirose

This figure shows the co-authorship network connecting the top 25 collaborators of Shunji Hirose. A scholar is included among the top collaborators of Shunji Hirose based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shunji Hirose. Shunji Hirose is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Funamoto, Masafumi, Shunji Hirose, Masaki Imanishi, et al.. (2025). Goreisan suppresses cardiac remodeling and dysfunction in a new mouse model with diabetic cardiomyopathy. Journal of Pharmacological Sciences. 157(2). 104–112.
2.
Kobayashi, Satoshi, Taito Fukushima, Makoto Ueno, et al.. (2024). Progression pattern and post‐progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma. Liver International. 44(6). 1343–1350.
3.
Sakakibara, Mamoru, Koichi Shiraishi, Yoshitaka Arase, et al.. (2024). Immune‐related adverse event detection in liver cancer patients treated with immune checkpoint inhibitors: Nationwide exploratory survey in Japan. Hepatology Research. 55(4). 547–555. 1 indexed citations
4.
Tsuruya, Kota, Shun Ono, Takuya Hara, et al.. (2023). First reports of clinical effects of transjugular intrahepatic portosystemic shunt in four patients with cirrhotic ascites refractory to tolvaptan. BMJ Open Gastroenterology. 10(1). e001120–e001120.
5.
Kobayashi, Satoshi, Taito Fukushima, Makoto Ueno, et al.. (2022). A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma. BMC Cancer. 22(1). 517–517. 7 indexed citations
6.
7.
Hirose, Shunji, Koshi Matsumoto, Masayuki Tatemichi, et al.. (2020). Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients. PLoS ONE. 15(11). e0241770–e0241770. 31 indexed citations
8.
Fukai, Kota, Koichi Shiraishi, Shunji Hirose, et al.. (2020). Hypothyroidism Is a Predictive Factor for Better Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Undergoing Lenvatinib Therapy. Cancers. 12(11). 3078–3078. 15 indexed citations
9.
Tsuruya, Kota, Yoshitaka Arase, Shunji Hirose, et al.. (2020). The Impact of a Heterozygous SLCO1B3 Null Variant on the Indocyanine Green Retention Test. Journal of Pharmaceutical Sciences. 109(10). 3206–3209. 5 indexed citations
10.
Hirose, Shunji, et al.. (2019). Complications during Sclerotherapy for Symptomatic Hepatic Cysts: Successful Bailout for Penetrating the Hepatic Artery and Portal Vein. Journal of Vascular and Interventional Radiology. 30(7). 1048–1049. 1 indexed citations
11.
12.
Arase, Yoshitaka, Kota Tsuruya, Shunji Hirose, et al.. (2019). Efficacy and Safety of 3‐Year Denosumab Therapy for Osteoporosis in Patients With Autoimmune Liver Diseases. Hepatology. 71(2). 757–759. 10 indexed citations
13.
Arase, Yoshitaka, Koichi Shiraishi, Hirohiko Sato, et al.. (2019). Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Clinical Drug Investigation. 39(7). 631–641. 22 indexed citations
14.
Hirose, Shunji, et al.. (2019). Rapid Regression of B-Cell Non-Hodgkin’s Lymphoma after Eradication of Hepatitis C Virus by Direct Antiviral Agents. Case Reports in Gastroenterology. 13(2). 336–341. 4 indexed citations
15.
Kagawa, Tatehiro, Shunji Hirose, Yoshitaka Arase, et al.. (2016). Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B. BMC Gastroenterology. 16(1). 38–38. 15 indexed citations
16.
Kagawa, Tatehiro, Koichi Shiraishi, Shunji Hirose, et al.. (2016). Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment. BMC Cancer. 16(1). 878–878. 17 indexed citations
17.
Hirose, Shunji, et al.. (2015). Study of the Psychological Factor of Bruxism : The Risk Flactor of Bruxism. 55(7). 864–872. 1 indexed citations
18.
Kagawa, Tatehiro, Shunji Hirose, Yoshitaka Arase, et al.. (2013). Ursodeoxycholic acid stabilizes the bile salt export pump in the apical membrane in MDCK II cells. Journal of Gastroenterology. 49(5). 890–899. 23 indexed citations
19.
Nagata, Junko, Shunji Hirose, Koichi Shiraishi, et al.. (2012). Vaginal bleeding in a patient with type C liver cirrhosis without a past history of laparotomy: successful treatment with partial splenic artery embolization. Clinical Journal of Gastroenterology. 5(4). 275–281. 4 indexed citations
20.
Mizukami, Hajime, Tatehiro Kagawa, Yoshitaka Arase, et al.. (2012). Complete Response after Short-Term Sorafenib Treatment in a Patient with Lymph Node Metastasis of Hepatocellular Carcinoma. Case Reports in Oncology. 5(2). 380–384. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cheng‐Hung Chien Breakdown of academic impact, for papers by Zheng‐Rong Shi Breakdown of academic impact, for papers by Andrea Mega Breakdown of academic impact, for papers by Kuan‐Chieh Fang Breakdown of academic impact, for papers by Anastasia Katsoula Breakdown of academic impact, for papers by Jung Wha Chung Breakdown of academic impact, for papers by Kosuke Tanaka Breakdown of academic impact, for papers by Ganesh Bhat Breakdown of academic impact, for papers by Takahiro Ozutsumi Breakdown of academic impact, for papers by Roberto Firpi-Morell
Rankless by CCL
2026